DNA sequence enrichment from complex genomic samples using microarrays enables targeted next-generation sequencing (NGS). In this study, we combined 454 shotgun pyrosequencing with long oligonucleotide sequence capture arrays. We demonstrate the detection of mutations including point mutations, deletions and insertions in a cohort of 22 patients presenting with acute leukemias and myeloid neoplasms. Importantly, this one-step methodological procedure also allowed the detection of balanced chromosomal aberrations, including translocations and inversions. Moreover, the genomic representation of only one of the partner genes of a chimeric fusion on the capture platform also permitted identification of the novel fusion partner genes. Using acute myeloid leukemias harboring RUNX1 abnormalities as a model system, three novel chromosomal fusion sequences and KCNMA1 as a novel RUNX1 fusion partner gene were detected. This assay has the strong potential to become an important method for the comprehensive genetic characterization of particular leukemias and other malignancies harboring complex genomes.
Introduction
DNA sequence enrichment from complex genomic samples has been proposed to enable a targeted next-generation sequencing (NGS) workflow. Several methods for massively parallel enrichment of the sequencing templates exist. Hybridization to customized microarrays containing synthetic oligonucleotides that match the target sequence allows capturing templates from randomly sheared, adaptor-ligated genomic DNA with high specificity. 1 Other methods are based on biotinylated RNA capture probes to capture size-selected genomic DNA in solution 2 or allow a simultaneous amplification of up to 4000 targeted sequences using microdroplet technology. 3 Today, the genetic characterization necessary for optimal treatment of leukemias requires a combination of different laborintensive methods, such as chromosome banding analysis and fluorescence in situ hybridization (FISH). 4 Characteristic leukemiaspecific fusion genes, detected by reverse transcriptase-PCR (RT-PCR) or direct sequencing, not only allow stratification of patients into distinct prognostic risk groups, 5, 6 but also serve as molecular markers to monitor minimal residual disease. [7] [8] [9] In this study, we combined 454 PicoTiterPlate (PTP) pyrosequencing with long oligonucleotide sequence capture arrays to evaluate whether this technique permits a comprehensive genetic characterization of a cancer genome. In particular, we addressed the question whether this combination of methods would detect not only point mutations, as well as deletions and insertions, but also capture target sequences that would reveal balanced chromosomal aberrations in a one-step procedure. This principle is proven by investigating the complex recombinome of leukemias harboring alterations in RUNX1, [10] [11] [12] [13] PDGFRB 14 and MLL. 15 At present, 32 chromosomal partner regions have been described for RUNX1 translocations, but the corresponding partner gene has only been identified in 17 translocations. 12 Similarly, 104 partner regions have been described for the MLL gene, but only 64 partner genes are molecularly characterized. 15 In this study, we further demonstrate that the contiguous genomic representation of only one of the partner genes of a chimeric fusion on the capture microarray assay was sufficient to identify also any potentially unknown partner gene from a balanced chromosomal aberration by subsequent shotgun sequencing.
Patients and methods

Patient cohort
In this study, we analyzed 19 acute leukemia cases (16 acute myeloid leukemias (AMLs), 3 acute lymphoblastic leukemias) and 3 patients with a myeloproliferative neoplasm sent to the MLL Munich Leukemia Laboratory for diagnostic procedures between October 2005 and September 2008 ( Table 1 ). All samples in this study were obtained from untreated patients at the time of diagnosis. The study design adhered to the tenets of the Declaration of Helsinki and was approved by the institutional review board before its initiation. Patients were diagnosed using cytomorphology, 16 chromosome banding analysis, FISH, 17 molecular genetics and flow cytometry. 18 
Molecular genetics
Standard mutational analysis by Sanger sequencing was performed on the purified fraction of mononuclear cells after Ficoll density centrifugation. Isolation of mononuclear cells, genomic DNA (QIAamp DNA Mini kit, Qiagen, Hilden, Germany), mRNA (MagNA Pure LC mRNA HS Kit, Roche Applied Science, Penzberg, Germany) and random primed complementary DNA synthesis was performed as described previously. 19 The analysis of KRAS mutations in codons 12, 13 and 61 was carried out as previously described. 20 Exons 2 and 3 were amplified by PCR, and PCR products were analyzed using the BigDye terminator v1.1 cycle sequencing kit (Applied Biosystems, Darmstadt, Germany). Analyses for NPM1 mutations, FLT3 internal tandem duplications, FLT3 tyrosine kinase domain mutations, KITD816 mutations and KIT exon 8 mutations were performed as described previously. [21] [22] [23] [24] [25] Targeted sequence capture microarray assay Briefly, 20 mg genomic DNA was fragmented by nebulization to small sizes of 300-500 bp to generate blunt-ended fragments. The DNA was quantified and the fragment size population was assessed by electrophoresis (Agilent Bioanalyzer 2100 DNA Chip 7500, Agilent, Bö blingen, Germany). The fragmented DNA was then processed according to the recommended NimbleGen protocol (Roche Applied Science, User Guide 3.1; July 2008). In brief, linkers were ligated to the polished fragments in the library to provide a priming site for post-enrichment amplification of the eluted fragment pool. The linker-terminated fragments were then denatured to produce single-stranded products that were exposed to the sequence capture microarray for hybridization for 72 h at 42 1C with active mixing using a MAUI hybridization station with mix mode B (Roche Applied Science). Any unbound DNA fragments were removed from the microarrays under stringent washing conditions and rinsed with Wash Buffers I, II and III (Roche Applied Science). Fragments captured on the microarrays were eluted with 125 mM NaOH and processed for amplification by ligation-mediated PCR using a primer complementary to the previously ligated linker oligonucleotides. The online section contains detailed information on the quality assessment of the different library preparation steps (Supplementary Figure 1 , Supplementary Table S1 ).
To quantify enrichment of the genomic DNA, four regions were selected for quantitative PCR measuring SYBR green fluorescence according to the manufacturer's protocols (Supplementary Figure 2) . The enriched and ligation-mediated PCR-amplified samples were compared against the non-enriched and ligation-mediated PCR amplified samples, that is, not hybridized to a capture array, using a LightCycler LC480 real-time PCR system (Roche Applied Science).
Microarray designs
A high-density oligonucleotide microarray representing capture probes covering 1.91 Mb of genomic sequences was synthesized according to a standard microarray manufacturing protocol (Roche NimbleGen 385K format). Overlapping microarray probes of more than 60 bases each on the array spanned each target genome region, with a probe positioned every 10 bases for the forward strand of the genome.
A first array captured short segments corresponding to all exon regions of 92 distinct target genes (genome build hg18). The genes had been selected according to their relevance in leukemia and included, for example, KIT, NF1, KRAS, CEBPA, NPM1, FLT3, IKZF1 or TP53 (in total: 1559 exons). In addition, contiguous genomic regions were represented for three additional genes, that is, CBFB, MLL and RUNX1. On the 385K chip, 96% of bases were covered by the design (Supplementary Spreadsheet 1).
Another series of three array designs represented a contiguous genomic region of a single target gene only (MLL, RUNX1 and PDGFRB). The RUNX1 gene was covered according to the following start and end coordinates: Chr. 21; 36 160 052-36 421 677 (261.5 kb; hg19 assembly). On the 385K chip, 97.6% of bases were covered by the design and RUNX1 was represented by capture probes with a 19-fold coverage on the capture microarray. The MLL gene was covered with the start and end coordinates: Chr. 11; 117 812 370-117 901 177 Figure 3-5 ).
Next-generation pyrosequencing
We applied NGS technology using 454 FLX Titanium chemistry according to the manufacturer's protocols (Roche Applied Science). 27 Sequencing-compatible linkers, including molecular barcode identifiers, were ligated to the eluted samples from the capture microarrays (Supplementary Table S2 ). The libraries were subsequently diluted, amplified on beads using emulsion PCR and sequenced using the 454 FLX sequencing instrument. One run comprised three patients per lane on a twolane PicoTiterPlate.
Sequencing data analysis
Basic raw data analysis was carried out using the GS Run Browser and GS Reference Mapper software version 2.0.01 (Roche Applied Science). Following in silico removal of the linker sequence, each sequence read was compared with the entire appropriate version of the human genome. Captured sequences mapped uniquely back to regions within the target regions were considered sequencing hits. These were then used to calculate the percentage of reads that did hit target regions, and the fold sequencing coverage for the entire target region. All putative variances were first compared with published singlenucleotide polymorphism (SNP) data (dbSNP build 130; http://www.ncbi.nlm.nih.gov/projects/SNP). Sanger sequencing and melting curve analyses were used independently of and concurrently with NGS sequencing to compare sequencing results in all patients.
Detection of chromosomal translocations and inversions
A specific analysis pipeline was developed for the detection of translocations and inversions. After image and signal processing, the reads were demultiplexed and linker sequences were removed. We applied the Burrows-Wheeler Aligner's Smith-Waterman algorithm 28 for mapping the trimmed reads against the reference genome. The Burrows-Wheeler Aligner's Smith-Waterman algorithm aligns chimeric reads and reports alignments largely non-overlapping on the query sequence, so that fewer alignment results enter the post-processing stage. To filter out any alignments of small interest with respect to translocations and inversions, we successively applied the following filtering processes: (Step 1) extract reads that have exactly two local alignments, ( Step 2) extract reads that have at least one local alignment within the target region, (Step 3) remove reads with a linker sequence between both local alignments and (Step 4) remove reads whose local alignments are on the same chromosome with a distance o1000 bp. These reads indicate smaller deletions or an insertion that are not focus of this pipeline but of the GS Mapper software and (Step 5) remove duplicated reads. Duplicated reads share the same 5 0 starting position and are likely caused by sequencing several PCR copies of the same original sequence. 29 Subsequently, the obtained reads were hierarchically clustered based on the Euclidean distance of their break points in base pairs. The distance between two break points from different chromosomes was set to infinity. Each remaining cluster represented a putative translocation or inversion. Most clusters consisted of a single read that was probably artificially generated during the sample preparation steps. 30 A detailed statistics summarizing dominant clusters and the following interpretation of fusion genes events is available online.
Results
Sequence capture enrichment performance and NGS raw data
Performance of the capture-enrichment process was assessed by quantitative PCR assays. These assays acted as a proxy for estimating the enrichment of larger populations of capture nucleic acid targets. Supplementary Spreadsheet 2 lists the individual median enrichment values of the sequence capture assay and corresponding array designs.
Performance of the actual sequencing process was assessed by several parameters (Supplementary Spreadsheet 2). In median, 168 230 reads were generated per patient (range 34 651-254 299). The median sequence length of these highquality reads was 324 per patient, and ranged from 214 to 384 bases. A median of 91.3% of reads mapped back uniquely to the genome. Of those reads that mapped back to the reference sequence, a median of 63% of reads were on-target for the chip design no. 1. Designs that only included a contiguous capture region for one gene each demonstrated a lower on-target read percentage (5.1%). Differences were also observed with respect to the occurrence of chimeric reads, wherein a median on-target read percentage of 44.9% for design no. 1 and 2.9% for the three subdesigns were detected, respectively. The median per-base coverage for each sample was 19-fold.
Detection of point mutations, deletions and small insertions
First, we analyzed five AML cases, processed with the custom 1.91 Mb microarray design no. 1, and aimed at confirming wellknown AML-typical mutations. In some of the samples tested, established mutations had been previously identified in routine diagnostics operations by conventional methods. As demonstrated in Supplementary Figure 6 , this targeted sequencing assay was able to detect the known insertion (case N06: FLT3 internal tandem duplication with 63 bp length mutation), deletion (case N01: KIT D419del) and point mutation (case N02: FLT3 tyrosine kinase domain D835Y; case N01: KRAS G12C).
Further, the enrichment assay also allowed identifying novel non-synonymous aberrations. Using sequence capture information from all 95 genes analyzed, in median 1701 variants were detected (case N01: 1984; case N03: 1745; case N04: 1500; case N05: 1701; case N06: 944). As highlighted in Supplemental Table S3 after stringent filtering according to known variations and SNPs only few exonic non-synonymous variants remained: case N01: 11; case N03: 6; case N04: 8; case N05: 6; case N06: 1. The final list of non-synonymous candidates included genes such as TET2 or PTPN11 and is currently being further investigated.
Detection of a balanced chromosomal inversion
To test the performance of the capture assay to reveal any balanced chromosomal aberrations, the microarray design no. 1 was Targeted next-generation sequencing in leukemia V Grossmann et al used to capture fragmented genomic DNA from an AML patient sample (case N01) harboring an inv(16)(p13q22) aberration, as detected by cytogenetics and FISH. On a molecular level, the CBFB gene was fused to MYH11, as confirmed by RT-PCR.
Applying a special data analysis pipeline, reads that did not uniquely map back to the reference genome were not discarded, but were analyzed further for the detection of chimeric sequences (Figure 1a) . In this case, a total of 12 reads were observed to carry sequence information that mapped both to the CBFB gene and the MYH11 gene, that is, four CBFB-MYH11 reads and eight MYH11-CBFB reads, respectively (Figure 1b) . These 12 chimeric reads had formed a dominant cluster in a background of 481 reads passing the analyses steps (Supplemental Spreadsheet 3). For example, sequence read no. 1 as given in Table 2 
). In addition, this assay allowed a high-resolution fine mapping of the break points (Table 2 and Supplementary Figure 7 ). As such, the combination of a sequence capture platform followed by NGS revealed a specific chimeric fusion gene resulting from a balanced inversion.
Detection of balanced translocations
Second, we investigated whether this method would also reveal any balanced translocations. In all, 11 cases were analyzed, in which previous cytogenetic and FISH analyses revealed balanced aberrations, involving translocations of the MLL, RUNX1 and PDGFRB genes, respectively. On a molecular level, PCR analyses had confirmed the presence of corresponding fusion genes (Table 1) . Case no. N40 is an example; a total of five reads was observed to carry sequence information that mapped both to the MLL and the AFF1 gene ( Figure 2 ). As such, by targeted capturing of MLL sequences using the chip design no. 2, subsequent shotgun sequencing confirmed the fusion partner gene as AFF1. The ability of this principle was also confirmed for 10 additional cases, that is, seven MLL fusions, one RUNX1 fusion and two PDGFRB fusions, respectively (Table 1) . A detailed summary statistics on the respective cluster size distribution for each fusion and the total number of clusters calculated from chimeric reads obtained for a given sample is available online (Supplemental Spreadsheet 3 and Supplementary Table S4 ).
Identification of unknown fusion partner genes
We next investigated nine patients with an aberrant karyotype, in whom FISH analyses had indicated balanced rearrangements of MLL and RUNX1 genes. First, we analyzed four AML cases, in which the capturing assay had detected fusions of MLL-MLLT1, MLL-MLLT6 and MLL-MLLT10 (Table 1) . Although the molecular testing of these fusion genes had been previously performed by RT-PCR during the initial diagnostic procedure, no fusion event was detected in these cases. However, NGS sequencing had revealed the occurrence of unusual break points, not allowing the routine primers to anneal, and thereby enable the detection of corresponding fusions. 
Raw sequences
Extraction of chimeric reads
Locally aligned sequences
Region 1: mapped to chr. 16q
Region 2: mapped to chr. 16p Figure 1 Identification of chimeric sequencing reads. (a) After processing of the raw image data, locally aligned sequences were identified using the Burrows-Wheeler Aligner's Smith-Waterman (BWA-SW) algorithm. 28 The local alignment is performed against the hg19 reference genome. In this exemplary case harboring an inv(16)(p13q22), 12 chimeric reads were detected mapping to distinct arms of chromosome 16. (b) Schematic orientation details for chimeric reads mapping to CBFB and MYH11 genes on chromosome 16. For CBFB-MYH11 and MYH11-CBFB fusions corresponding chromosomal start and end coordinates are given.
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Second, in another case, a translocation t(11;19)(q23;p13) had been observed in chromosome banding analysis and the involvement of the MLL gene had been proven by FISH. However, using RT-PCR neither MLL-MLLT1 (ENL) nor MLL-ELL fusion transcripts were amplified to confirm any molecular aberration. In contrast, the NGS method identified chimeric reads. Five reads were observed to carry sequence information that mapped to the MLL gene on the plus strand of chromosome 11 and additional partner genes on the minus strand of chromosome 19 (Figure 3a) . Two sequence reads corresponded to an MLL-ELL fusion. In addition to MLL and ELL reads, three chimeric reads were detected which were composed of SFRS14 (splicing factor, arginine/serine-rich 14), also located on 19p13 centromeric of ELL. By applying RT-PCR and subsequent Sanger sequencing with new primers designed based on the NGS data we were able to confirm both the MLL-ELL fusion and the novel SFRS14-MLL fusion. However, we did not detect a corresponding ELL-MLL fusion gene. This suggested that a deletion had occurred in the break point area, and thus prevented the formation of the reciprocal ELL-MLL fusion gene. To confirm this assumption, we performed a SNP microarray analysis (Affymetrix genome-wide human SNP array 6.0, Santa Clara, CA, USA) and Table 2 Chimeric reads identified for a case (N01) with inv (16) Figure 2 Detailed distribution of chimeric sequencing reads. A total of five chimeric fusion sequences were observed for an acute lymphoblastic leukemia case N40 with t(4;11)(q21;q23). Two reads detected the MLL-AFF1 fusion and three reads detected the AFF1-MLL fusion, respectively. data from the SNP microarray demonstrated a 615 kb deletion on 19p13, flanked by ELL and SFRS14. As such, a microdeletion was causative for the fusion of SFRS14 to MLL in the reciprocal setting and could be deciphered by NGS (Figure 3b ). In another series of four cases (three AML, one CMML) RUNX1 abnormalities were observed by metaphase cytogenetics and FISH (Figure 4a ). Data on a comprehensive molecular mutation screening is given in Table 3 . In this study, capture and enrichment of RUNX1 DNA fragments followed by shotgun sequencing enabled the discovery of four novel distinct fusions (Table 1) . In one case, KCNMA1 was fused to RUNX1. This gene, a potassium large conductance calcium-activated channel family member on chromosome 10q22.3, has been reported to be fundamental to the control of smooth muscle tone and neuronal excitability. [31] [32] [33] In our patient the RUNX1-KCNMA1 fusion, as confirmed by RT-PCR and Sanger sequencing, led to the disruption of the 'Runt homology domain' (RHD) of RUNX1 (Figure 4b ). The break point in RUNX1 was detected in intron 3-4 (ENST00000300305), whereas in t(8;21) the genomic break point is located in intron 5, after the RHD domain. 34, 35 The break point in the KCNMA1 gene, encoded by 27 exons, was located in intron 19-20 (ENST00000286627) . Because of the frameshift in exon 20 in KCNMA1, the second codon is predicted to be translated into a stop codon. Therefore, this translocation results in a chimera consisting of a truncated RUNX1 gene fused to a single amino acid of KCNMA1 (Figure 4b) .
In three cases, RUNX1 was observed to be fused to genomic regions on chromosomes 17q21, 5q13.3 and 10q22, respectively (Figure 4b) . Interestingly, these fusion sequences would not lead to connecting RUNX1 to a known candidate gene, and consequently were not detectable on a transcript level. The RUNX1-10q22 and the reciprocal 10q22-RUNX1 fusion were confirmed by PCR from genomic DNA and subsequent Sanger sequencing (Supplementary Table S5 ). In the latter two cases, only the reciprocal fusion events (chr. 17q-RUNX1 and chr.5q-RUNX1) were detectable.
Discussion
In this study, we described the specific capture and enrichment of target nucleic acids, and the subsequent analysis of the enriched target nucleic acids for detecting balanced chromosomal aberrations, including translocations and inversions, in a leukemia genome. In particular, we were able to demonstrate that the format of representing one fusion partner gene on a capturing platform allowed the subsequent sequencing of chimeric nucleic acids, that is, single DNA molecules mapping to different regions of a genome, and thereby enabling the identification of novel fusion partner genes occurring as a result of a balanced chromosomal translocation.
For target enrichment, a programmable high-density microarray platform with 385 000 probes was used. The probes were able to capture up to 5 Mb of total sequence. Recently, this workflow was shown to also allow analysis of all human exons using a 2.1 million feature capture array. 36 In our study, the capture-enrichment process targeted genes reported to have a pathogenetic role in hematological malignancies, for example, as part of molecular fusion genes resulting from translocations or inversions. Overall, the capture and enrichment process provided a useful purification of unique genomic sequences away from repeats and other impurities that would confound, for example, the first emulsion PCR step of the 454 sequencing process. Therefore, in addition to the specificity of the assay, the high yields of the downstream DNA sequencing steps are consistently superior to the routine average performance of shotgun sequencing using non-captured DNA sources.
In principle, we observed that specific sequence enrichment by a 'larger' array design, that is, the one covering 1.9 Mb of targets and containing multiple genes and contiguous genomic regions, had outperformed the smaller 'single gene' designs with probes querying only 41.5 kb (PDGFRB), 81.7 kb (MLL) and 255.2 kb (RUNX1), respectively. The larger target design had resulted in a median on-target percentage of 63.0%, whereas lower on-target percentages were observed for the gene-wise designs (5.1%), as listed in Supplementary Spreadsheet 2. Thus, the capturing performance indeed can be improved if multiple genes and genomic loci are enriched on the same array. Yet, as we learned from these data, there might be a general limit in coverage, as both design strategies resulted in a similar median sequencing coverage: 19-fold coverage (large design) versus 17-fold median coverage (gene-wise design). This can be interpreted in a way that using the smaller designs the target is completely depleted from the DNA specimens so that increased unspecific hybridizations do occur and, as such, the on-target enrichment performance is less effective. This is further illustrated by case N16 (MLL design), in which the on-target capturing efficacy was as low as 6.8%, yet this experiment still resulted in 53-fold coverage of the targeted MLL gene, and yielded 31 chimeric on-target reads. Similarly, in case N27, a comparable number of 38 chimeric on-target reads were Abbreviations: ITD, internal tandem duplication; Pos., positive; wt, wild type.
Targeted next-generation sequencing in leukemia V Grossmann et al generated for RUNX1, although in this enrichment assay only 1.6% of reads were observed to be on-target (onefold coverage; high amount of unspecific enrichment). Overall, the sequencing output is in line with recently published data from a similar design strategy, in which a 2 Mb sequence capture array was used to study autosomal recessive ataxia. 37 In this study, an analysis pipeline was used to map the obtained reads both exactly against the human genome to detect point mutations, small deletions and insertions, but also to identify chimeric sequences mapping to different regions in the genome. Focusing on the first five patients, analyzed using the 1.9 Mb capture array for 95 gene targets, after stringent filtering a median of 247 exonic variants was observed. Filtering-out known variations, untranslated or synonymous variants, in median only six variants per case were observed. Yet, at this stage the majority of final non-synonymous variants, with the exception of those already described in the Supplementary Material in more detail, will remain putative and are currently under further investigation.
Second, by this approach, all fusion genes previously known from cytogenetics, FISH and standard molecular analyses were detected, for example, CBFB-MYH11, MLL-MLLT3, ETV6-RUNX1 and RUNX1-RUNX1T1, respectively. Moreover, this method allowed resolving fusion events with unusual break points, in which routine diagnostics primers were not annealing. For example, in case N05 cytogenetic analysis revealed a translocation t(11;19)(q23;p13), and FISH confirmed the MLL rearrangement. However, molecular PCR-based assays failed to reveal the translocation partner gene. The method presented in our study in combination with SNP microarray analysis elucidated MLL-ELL and a novel SFRS14-MLL fusion resulting from a t(11;19)(q23;p13), including a 615 kb deletion on 19p13.
Importantly, the genomic representation of only one of the partner genes of a chimeric fusion on this capture assay was sufficient to identify also any potentially unknown partner gene as a result of a balanced chromosomal aberration. However, as break points can also occur in intron sequences, a contiguous genomic representation of all exons and introns is mandatory.
As such, we further aimed at elucidating the role and mechanism of RUNX1 translocations. RUNX1 is a crucial transcription factor involved in cell lineage differentiation during hematopoiesis. 38 It contains a RHD and a transactivation domain. RUNX1 can function as activator or repressor of target gene expression, and three distinct modes of leukemogenesis due to acquired alterations of the RUNX1 gene have been recognized: point mutations, amplification and translocation. 12 Most of the translocations involving RUNX1 lead to the formation of a fusion gene consisting of the 5 0 part of RUNX1 fused to sequences on other chromosomal regions. Translocations that retain the RHD but remove the transcription activation domain have been reported to demonstrate a leukemogenic effect by acting as dominant-negative inhibitors of wild-type RUNX1 in transcription activation. 12 In our cohort, one case (N30) was discovered to harbor a fusion sequence RUNX1-chr.10q22 that will be translated into a truncated RUNX1 protein with an intact RHD, but without transactivation domain because of the break point in intron 6-7. Because of the loss of the splice acceptor site, sequences of RUNX1 intron 6-7 and a part of the sequence on chromosome 10 will be translated until a stop codon is located. However, only the first 96 amino acids of intron 6-7 will be translated, as a stop codon is located even before the break point. Thus, this chromosomal translocation resulted in a truncated RUNX1 that resembles functionally more a point mutation with absence of a real fusion gene.
Second, nonsense and frameshift mutations in the N-terminal region result in partial deletion of the RHD and total loss of the C-terminal region. Thus, these types of alterations predict the loss of DNA-binding capability and trans-activating potential of RUNX1. 39 In this study, we describe a novel RUNX1-KCNMA1 fusion (N28). To our knowledge, this is the first report of a RUNX1 fusion to a large-conductance calcium-and voltageactivated potassium channel. 12 Recently, KCNMA1 has also been described to have a role in breast cancer invasion and metastasis to brain. 32 In line with the mechanism described above, this translocation resulted in a predicted truncated RUNX1 protein with disrupted RHD fused to a single amino acid of KCNMA1.
These mutations generally do not have a dominant-negative effect on the wild-type RUNX1, as a truncated RUNX1 leads to a haploinsufficiency for this gene. 40 Studies on knock-out mice have demonstrated that loss of one Runx1 allele causes a 50% reduction in the number of hematopoietic stem cells, suggesting that its function is dose dependent. 40, 41 In our study, two cases with loss of one RUNX1 allele due to chromosomal fusions can be postulated. In this study, RUNX1 was fused to genomic regions on chromosomes 5q13.3 and 17q21, respectively. However, only the reciprocal fusion events, that is, chr. 17q-RUNX1 and chr. 5q-RUNX1, were detectable by PCR.
Although, in both cases a second cooperative step is important, families with mutations acting simply via haploinsufficiency have a lower incidence of leukemia than families with mutations acting in a dominant-negative manner. 42 Haploinsufficiency seems to be the basis for pathogenesis, but a mechanism other than genuine haploinsufficiency is important for leukemogenesis, 41, 42 as in addition to RUNX1 alterations second cooperating hits are required to drive leukemic mechanisms. 43 Molecular genetic and cytogenetic analyses help to identify these second cooperating hits. For example, patients with RUNX1 point mutations show the following concurrent abnormalities: þ 21; À7; þ 8; þ 13. 41, 42 Loss of chromosome 7 is suspected to be a strong predisposing factor for the second hit in a RUNX1 þ /À background (case N29). FLT3 mutations are also cooperating genetic alterations. RUNX1 results in a differentiation blockade, whereas FLT3 mutations are simultaneously responsible for growth stimulation. 42 In our cohort, different secondary molecular mutations were observed and included aberrations in NRAS and KRAS.
In conclusion, we demonstrated that the combination of a targeted DNA sequence enrichment assay followed by NGS technology allowed characterizing a complex cancer genome. As such, this assay revealed balanced genomic aberrations, which are detectable thus far only by metaphase cytogenetics and FISH, that is, laboratory methods that typically are laborintensive and require expert-knowledge. Therefore, this NGS assay has the potential to become an important diagnostic method, especially for tumors in which cytogenetics can not be applied successfully. Of note, thus far SNP microarrays are not capable of detecting balanced chromosomal aberrations either. Yet, implementation of such a technique in a clinical laboratory is challenging. Daily routine usage of such novel genomic approaches is currently limited by the high costs associated with this assay and, moreover, by the relatively long turn-around time. In an ideal setting, data from such a targeted enrichment assay would be available no earlier than eight laboratory working days, although allowing sequencing hundreds of genes in a targeted manner. On the other hand, it would be technically not possible to cope with this high number of amplicons, if one would perform conventional Sanger sequencing for these high number of targets. Related to balanced chromosomal Targeted next-generation sequencing in leukemia V Grossmann et al aberrations, fusion genes, point mutations, as well as deletions and insertions were detected in a one-step methodological approach. Finally, the genomic representation of only one of the partner genes of a chimeric fusion on this capture assay was sufficient to identify also any potentially unknown partner gene from a balanced chromosomal aberration.
